[THE INVESTOR] Genexine announced the preliminary report of its phase 2 clinical trial for GX-H9, its longer half-life human growth hormone, on Sept. 12 at the European Society for Pediatric Endocrinology 2016 in Paris.

The South Korean biopharmaceutical company released a mid-development report at the annual meeting saying that the bimonthly dose of its hormone has been found safe and effective in the multinational clinical trials on children with growth hormone deficiency. 




The final results from phase 2 clinical trials on pediatric patients will be available in the first half of 2017, and those on adult patients will be released by the end of this year, the company said.

By Hwang You-mee (glamazon@heraldcorp.com)